Bellus Medical Wins the Barry Knapp Award for Product Innovation of the Year

This Win Represents the Ninth Win for Bellus Medical in Two Months

 

JOHNSON CITY, TN, AND DALLAS, TX (PRWEB) December 5, 2018 

Bellus Medical, a premier medical aesthetics team, again proved its leading SkinPen Precision device is setting a new standard as the premier FDA-cleared microneedling device. This award comes on the heels of its record-setting Aesthetics Everything win.

Each year this award is presented at the renowned Aesthetics Awards to products launched in the U.K. that represent genuine innovation or product advancement leading to treatment for new indications, quicker or easier treatments, better treatment outcomes, enhanced patient safety, backed up by sound evidence. The product scored extremely well with the judges, with one commenting, “An important innovation within the generic microneedling sector… I believe this product represents a benchmark for safety and quality in microneedling.”

“Bellus Medical, in partnership with BioActiveAesthetics, is honored to have received this prestigious award. SkinPen is a first in class technology that delivers safe and effective results,” said Joe Proctor, President of Bellus Medical. “We are thankful to Medical Aesthetics Group for recognizing our innovation in aesthetics. I was especially proud to have received the award with Jenn Block and Thomas Hitchcock, Ph.D. who worked together to finalize the development process. I would like to share a special thank you for Ashley Dynan who worked so hard to get the CE Mark in the UK. It’s a great win for the Crown family, and we are looking forward to continuing to innovate and improve technology in the field of Dermatology and Aesthetics.”

“After all the time, resources and effort that went into the development of Precision, it has been very satisfying to see how well the device has been accepted by the medical community. Additionally, to see it winning awards both in the United States and now internationally has been quite validating,” said Crown’s Chief Science Officer, Thomas Hitchcock, Ph.D. “We took a risk in redesigning the microneedling device from the ground up, and we are pleased to see that the innovation and thoughtful engineering that went into Precision is what our customers wanted in a next-generation microneedling device.”

About Bellus Medical 
Bellus Medical, a premier medical aesthetics team and a division of Crown Laboratories, is dedicated to helping industry-leading plastic surgeons, dermatologists, and aesthetic physicians around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our goal is to draw new consumers into practices and we that with our non-invasive “gateway” innovations:

  • SkinPen, the first FDA-cleared microneedling device;
  • Skinfuse®, the post-microneedlingprotocol
  • Allumera®, light-activated cream
  • ProGenTMand RegenLab®, our platelet-rich plasma systems

Based in Dallas, Texas, Bellus sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. Learn more at bellusmedical.com.

About Crown Laboratories, Inc.
Crown Laboratories, Inc. is a privately held, fully integrated global skin care company. Crown Laboratories is committed to developing and providing a diverse portfolio of beauty, consumer, OTC, prescription, medical and aesthetic skin care products that improve the quality of life for its customers. In addition, Crown Laboratories also provides pharmaceutical development and contract manufacturing services for a host of partners world-wide. As an innovative company with key products such as its recently acquired, first FDA-cleared medical grade microneedling device, SkinPen, Blue Lizard Australian Sunscreen, Vita Liberata sunless tanning and skin care, and robust portfolio of Rx and OTC products, Crown Laboratories has enjoyed rapid growth and is poised to become a leader in Dermatology. Crown Laboratories has been listed on the Inc. 5000 Fastest Growing Companies List for six consecutive years. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com. 

About BioActiveAesthetics
BioActiveAesthetics is an experienced and dynamic distribution company launching new and innovative products internationally using unrivalled expertise and core knowledge of the industry in the Professional Health, Beauty and Aesthetics Arena spanning 25 years.

The Managing Director – Kathy Taylor-Brewin has always had the ability to spot the next trend, whether it is equipment or product, Supporting, promoting or selling to the industry via a network of industry professionals built over many years.

The UK market is a small but mature and sophisticated market.  BAA offers an understanding and passion of the industry from grass roots up, the key to their success is a real understanding of the professional Arena which can only be gained through experience.

BAA offers the drive and enthusiasm required with the ability to understand the end user’s needs providing the key attributes to make a success of new innovations that is required for unknown brands to develop and succeed in the medium to long term.

About the Aesthetics Awards
The Aesthetics Awards, in association with Aesthetics Media Ltd, brings together the very best in medical aesthetics and leaders in the profession to celebrate the achievements of the past year. The prestigious ceremony recognizes those who have truly excelled in the field of medical aesthetics, from clinics and individual practitioners, to manufacturers and suppliers. The Awards create buzz, excitement, awareness and a chance to reward and recognize those who successfully contribute to the expanding and exciting specialty.

 

Contact:
Jill McGonigle
978-866-4931
jmcgonigle@crownlaboratories.com

FOR IMMEDIATE RELEASE

 

CROWN LABORATORIES ACQUIRES SELECT CONSUMER
HEALTHCARE BRANDS FROM GLAXOSMITHKLINE

 

Hildred Capital Portfolio Company Enhances OTC Skin Care Product Offerings

 

November 30, 2018 Johnson City, TN Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated skin care company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced it has acquired North American distribution rights of five (5) OTC consumer brands from GlaxoSmithKline (“GSK”).

GSK’s consumer healthcare portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and their patients the ability to access therapeutic products while reducing the burden of prescription drug costs on the healthcare system. The products expand Crown Laboratories’ consumer portfolio by adding #1 in category brands that treat multiple conditions. The acquired portfolio includes:

  • PanOxyl®: #1 Dermatologist recommended daily acne wash
  • Sarna®: #1 Dermatology recommended anti-itch lotion
  • Zeasorb®: #1 Dermatologist recommended anti-fungal and prevention product
  • Desenex®: Anti-fungal powder for athlete’s foot
  • Mineral Ice®: Leading pain-relieving gel

The brands all have a strong heritage and lengthy history in the market.  PanOxyl, Sarna, and Zeasorb are three (3) former Stiefel Laboratories, Inc. brands that have earned #1 Dermatologist Recommended status through decades of strong support from dermatologists. “Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” said Jeff Bedard, Crown Laboratories President and CEO. “I am especially excited to bring the Stiefel brands to Crown as I personally enjoyed tremendous success in marketing them as a field sales representative for Stiefel in the 80’s and 90’s.”

“Facilitating the addition of these highly regarded brands reinforces Hildred’s commitment to work with Crown to build a diversified business with high quality product offerings across all aspects of dermatology and skin care,” added David Solomon, Partner of Hildred Capital Partners, LLC and Chairman of Crown Laboratories. “The addition of these brands provides meaningful diversification for our OTC portfolio and enhances our breadth of trusted consumer skin care therapies. We will continue to look for interesting opportunities to build on Crown’s consumer healthcare, aesthetic and prescription product lines.”

Crown Laboratories has chosen the Emerson Group to manage the sales activity and all logistics for the PanOxyl, Sarna, Zeasorb, Desenex, and Mineral Ice brands across all retailers. “We are extremely excited to partner with Crown Laboratories,” said Scott Emerson Chairman and CEO of the Emerson Group. “Crown’s management team, dermatology expertise and enhanced resources will serve the acquired brands well in a very attractive growth category for our retailers.”

Financial terms of the transaction were not disclosed. Lowenstein Sandler, LLP acted as legal advisor to Crown Laboratories and Hildred, while Hayfin Capital Management, LLP provided debt financing in connection with the transaction. Crosstree Capital Partners New York, LLC and Latham & Watkins (London) LLP served as financial and legal advisors, respectively, to GlaxoSmithKline.

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated global skin care company. Crown Laboratories is committed to developing and providing a diverse portfolio of beauty, consumer, OTC, prescription, medical and aesthetic skin care products that improve the quality of life for its customers. In addition, Crown Laboratories also provides pharmaceutical development and contract manufacturing services for a host of partners world-wide. As an innovative company with key products such as its recently acquired, first FDA-cleared medical grade microneedling device, SkinPen, Blue Lizard Australian Sunscreen, Vita Liberata sunless tanning and skin care, and robust portfolio of Rx and OTC products, Crown Laboratories has enjoyed rapid growth and is poised to become a leader in Dermatology. Crown Laboratories has been listed on the Inc. 5000 Fastest Growing Companies List for six consecutive years. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

 

About Hildred Capital Partners

Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

 About The Emerson Group

The Emerson Group has been facilitating transition to the changing consumer retail economy for over 20 years. With a field sales infrastructure of 10 regional offices, Emerson manages CPG brands in excess of $3.8 billion, and holds equity positions with small and medium-size brands. It also operates internationally, providing partners in the European, South American and Asian Pacific regions with the expertise and infrastructure necessary to successfully operate in the U.S. market.

The company offers clients unparalleled retail relationships, advanced turnkey logistics, comprehensive marketplace analytics, and access to equity markets. Emerson Logistics, the #5 HBC supplier to the trade, is an efficient turnkey logistics solution, delivering on-time and complete shipments, single purchase orders for multiple products, single point of contact for multiple vendors, and reduced processing costs. Emerson Marketing partners with industry-leading experts to leverage data and shopper insights for clients, with up-to-the-minute category and brand information.

The Emerson organization’s resources and expertise has been expanded into Canada with our recent merger with McCaughey Consumer Products Management, Inc., a leading Canadian sales organization offering national account management, brand management, inventory management, accounts receivable and quality control. To learn more visit www.emersongroup.com.

 

Forward Looking Statements

In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

 

Contact:

For Crown Laboratories:

Jill McGonigle, 978-866-4931

jmcgonigle@crownlaboratories.com

or

For Hildred:

Reevemark

Hugh Burns/Molly Curry, 212-433-4600

FOR IMMEDIATE RELEASE

 

CROWN LABORATORIES ANNOUNCES ADDITION OF
THOMAS HITCHCOCK, PHD TO THE LEADERSHIP TEAM

 

Thomas Hitchcock, Ph.D. Joins Crown Laboratories as Chief Science Officer

 

November 20, 2018 Johnson City, TN Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated skin care company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced the appointment of Thomas Hitchcock, Ph.D. as Chief Science Officer. Dr. Hitchcock will oversee Medical Affairs, R&D and Clinical Development for all Crown brands and will hold a Leadership Team position.

Dr. Hitchcock is the Founder of Xycrobe Therapeutics Inc. (http://www.xycrobe.com) and has served as its Chief Executive Officer. Additionally, Dr. Hitchcock served as the Acting Chief Scientific Officer and Vice President of Clinical & Medical Affairs at Bellus Medical from its inception in 2013 up to the acquisition by Crown Laboratories last month. He has more than 20 years of research experience including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial plastic surgery, Dermatology and Aesthetic medicine.

Jeff Bedard, President and CEO of Crown Laboratories said, “I am delighted to welcome Dr. Hitchcock to Crown. Dr. Hitchcock will be working diligently to move our growing pipeline through the approval and commercialization process. Under Dr. Hitchcock’s leadership and guidance, we look forward to building a strong network of academia to guide us along the path of achieving successful commercialization of current and future products.”

“I’m thrilled to be joining Crown during this time of accelerated growth.” says Dr. Hitchcock. “Given the company’s diverse portfolio and pipeline, my background and expertise align nicely with the organization’s path forward and I am excited at the opportunity to contribute to the innovation across all Crown brands. Innovation, unique technology, and strong leadership will be critical to our success and I am eager to continue to build out the scientific side of the business and help drive the company forward. I have no doubt we have a strong future ahead of us,”

Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College where he studied multiple myeloma genetics. He also performed his Post-doctoral Research in tissue engineering and regenerative medicine at Yale University. During this time, he was first to successfully implant a tissue-engineered human small-diameter artery into a living host. His findings have been presented internationally and printed in a number of noteworthy publications including the Journal of Biological Chemistry, the Annals of the New York Academy of Sciences and a chapter on energy-based devices in Clinics in Plastic Surgery. Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed postdoctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics.

 

 

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated global skin care company. Crown Laboratories is committed to developing and providing a diverse portfolio of beauty, consumer, OTC, prescription, medical and aesthetic skin care products that improve the quality of life for its customers. In addition, Crown Laboratories also provides pharmaceutical development and contract manufacturing services for a host of partners world-wide. As an innovative company with key products such as its recently acquired, first FDA-cleared medical grade microneedling device, SkinPen, Blue Lizard Australian Sunscreen, Vita Liberata sunless tanning and skin care, and robust portfolio of Rx and OTC products, Crown Laboratories has enjoyed rapid growth and is poised to become a leader in Dermatology. Crown Laboratories has been listed on the Inc. 5000 Fastest Growing Companies List for six consecutive years. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

 About Hildred Capital Partners

Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

Forward Looking Statements

In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

 

Contact:

For Crown Laboratories:

Jill McGonigle, 978-866-4931

jmcgonigle@crownlaboratories.com

or

For Hildred:

Reevemark

Hugh Burns/Molly Curry, 212-433-4600

FOR IMMEDIATE RELEASE

CROWN LABORATORIES ACQUIRES BELLUS MEDICAL

Hildred Capital Portfolio Company Establishes Aesthetics Division
with Innovative, Non-Invasive Product Line

September 27, 2018 – Johnson City, TN & Addison, TX – Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated, specialty pharmaceutical company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced it has acquired Bellus Medical, a leader in medical aesthetics treatments dedicated to delivering innovative repair and restoration products to aesthetic practices around the world.

Bellus’s non-invasive products give it a unique position in aesthetics, providing a range of products that draw first-time consumers to leading physician-directed practices globally. Most notable among its products is the SkinPen® – a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars – the first microneedling device in the industry to be granted clearance and marketing authorization by the U.S. Food and Drug Administration (FDA) for this indication. Bellus’s full line of innovative products and devices includes:

• SkinPen®: the first ever FDA-cleared microneedling device for the treatment of acne scarring
• Skinfuse: post-microneedling protocol
• Allumera: light-activated cream
• ProGenTM / RegenLab: platelet-rich plasma systems

Bellus Medical will become the new Aesthetics Division of Crown Laboratories and be renamed Bellus Aesthetics. Bellus will continue to be based in Dallas, Texas and operate as a wholly-owned subsidiary of Crown Laboratories. Bellus CEO Joe Proctor will become President of Crown’s Aesthetics Division and join the Crown Board of Directors.

“Partnering with Bellus is a truly exciting and significant first step in building our Aesthetics Division,” said Jeff Bedard, Crown Laboratories President and CEO. “Bellus has assembled a truly impressive team with an enviable track record of innovation in aesthetics, exemplified by the SkinPen®, the first ever FDA-cleared microneedling device for acne scarring. We believe there is a tremendous opportunity for us in aesthetics, and with Bellus as the cornerstone of our new division, we expect to expand our portfolio meaningfully in the years ahead.”

“We are thrilled to have found such a compelling opportunity with a partner that shares our vision and approach to growing the business and improving patient outcomes,” said Joe Proctor, Bellus Medical CEO. “The Crown Labs organization is culturally compatible and brings us the additional resources we need to expand our infrastructure, support future growth, and better serve our valued network of providers. This transaction represents a unique opportunity to build Bellus into an elite aesthetics company and we look forward to joining with our new colleagues and to building the Crown aesthetics franchise.”

“On behalf of Hildred, I am delighted to work with Crown on launching its new Aesthetics Division and to welcome Joe and his colleagues to the team,” said David Solomon, Hildred Partner and Chairman of the Board for Crown Laboratories. “With its unique market position and portfolio, led by the first ever recognized Class II microneedling device, Bellus represents an exciting opportunity for Crown, complements its current skincare offering and expands its potential to grow and drive future consolidation. We will continue to look for distinct and attractive opportunities to build on Crown’s consumer healthcare and prescription product lines – and now its aesthetic product line – with the launch of this new division.”

Financial terms of the transaction were not disclosed. Lowenstein Sandler, LLP acted as legal advisor to Crown Laboratories and Hildred, while Hayfin Capital Management, LLP provided debt financing in connection with the transaction. Piper Jaffray and Perkins Coie served as financial and legal advisors, respectively, to Bellus Medical.

Earlier this month, Montreux Equity Partners completed a growth capital financing in Crown Laboratories out of its new healthcare growth capital fund, Montreux Growth Partners II, L.P. With the financing, Crown continues to broaden its distribution across existing channels, and add new product lines to support its growth as a leading player focused on dermatology.

About Crown Laboratories, Inc.
Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company, focused in dermatology and committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories is an innovative company, whose Blue Lizard Australian sunscreen, Vita Liberata organic sunless tanning and skincare, and robust portfolio of dermatological products have paved the way for Crown Laboratories’ rapid growth. Crown Laboratories’ prescription portfolio includes key branded products AlaScalp, AlaQuin and Tri-Derm. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

About Hildred Capital Partners
Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

About Bellus Medical
Bellus Medical, headquartered in Addison, TX, is an industry leader in medical aesthetics with an unmatched reputation of providing the highest levels of safe and effective products and the most innovative technology on the market. Founded in 2012, Bellus quickly became an industry pioneer with the introduction of its flagship product SkinPen®, a state-of-the-art microneedling device, which was the first ever FDA-cleared medical grade microneedling device on the market. Bellus’ product portfolio continually expands with unique and differentiated products developed to enhance the patient experience and represent a significant business opportunity for medical practices. Built upon three guiding principles – technology, education and customer service – Bellus is much more than a supplier to aesthetic practices, it is a trusted business partner. To learn more about Bellus Medical, visit www.BellusMedical.com.

About Montreux Equity Partners
Montreux Equity Partners is dedicated to making growth capital investments in high growth, category-leading companies with products, technologies and services that are advancing health. Founded in 1993, Montreux has invested in more than 60 companies, including MINDBODY (Nasdaq: MB), Glaukos (NYSE: GKOS), Tobira Therapeutics (acquired by Allergan), MAKO Surgical (acquired by Stryker), SkinMedica (acquired by Allergan) and Renal CarePartners (acquired by Ambulatory Services of America). Montreux is based in San Francisco, CA, and is currently investing out of its second healthcare growth capital fund, Montreux Growth Partners II, L.P. For more information about Montreux Equity Partners, visit www.mepvc.com.

Forward Looking Statements
In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

Contact:
For Crown Laboratories:
Libby Erwin, 423-630-2269
lerwin@crownlaboratories.com
or
For Hildred:
Reevemark
Hugh Burns/Molly Curry, 212-433-4600

# # #

For the 6th Consecutive Year, CROWN LABORATORIES, INC. Appears on the Inc. 5000 List

August 15, 2018

JOHNSON CITY, TN – Inc. magazine today revealed that CROWN LABORATORIES, INC. is No. 3955 on its 37th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. Only six percent of companies have made the list 6 consecutive times. Crown Laboratories, Inc. is honored to be included on the list. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment – its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow and many other well-known names, gained their first national exposure as honorees on the Inc. 5000.

“Crown is incredibly honored to be recognized with this distinction for the 6th time in a row,” says Jeff Bedard, Crown Laboratories, Inc. President and CEO. “To be recognized by Inc. and to be part of the group of companies on the Inc. 5000 list is truly an honor.” “We owe a debt of gratitude to our outstanding employees, that through their hard work, made this honor happen.”

The companies on the 2018 Inc. 5000 (which are listed online at Inc.com, with the top 500 companies featured in the September issue of Inc., available on newsstands August 15) have been very competitive within their markets. The list as a whole, shows staggering growth, compared with prior lists. The 2018 Inc. 5000 achieved an astounding three-year average growth of 538.2 percent and a median rate of 171.8 percent. The Inc. 5000’s aggregate revenue was $206.1 billion in 2017, accounting for 664,095 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database, that can be sorted by industry, region and other criteria, can be found at www.inc.com/inc5000.

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories, Inc. is an innovative company on the move, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown’s rapid growth.

For more information about Crown Laboratories or its products, visit www.crownlaboratories.com. Contact: Libby Erwin @ 423-630-2269 or lerwin@crownlaboratories.com.